Skip to Content
Merck
  • MicroRNA-1271 inhibits the progression of papillary thyroid carcinoma by targeting IRS1 and inactivating AKT pathway.

MicroRNA-1271 inhibits the progression of papillary thyroid carcinoma by targeting IRS1 and inactivating AKT pathway.

European review for medical and pharmacological sciences (2019-10-11)
Y Chen, S-A Hao, Y Jiang, B Gao, W-G Tian, S Zhang, L-J Guo, L-L Wang, D-L Luo
ABSTRACT

The important role of microRNA-1271 (miR-1271) has been identified in human diseases and cancers. However, the biological function of miR-1271 remains ambiguous in papillary thyroid carcinoma (PTC). Therefore, the specific role of miR-1271 was investigated in PTC. The expressions of miR-1271 and insulin receptor substrate 1 (IRS1) were detected by quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) assay. The protein expression of the genes was measured by Western blot analysis. The function of miR-1271 was investigated using methyl thiazolyl tetrazolium (MTT) and transwell assays. The Dual-Luciferase assay was used to observe the relationship between miR-1271 and IRS1. MiR-1271 was downregulated in PTC tissues. Moreover, overexpression of miR-1271 suppressed migration, invasion and proliferation of PTC cells. Furthermore, IRS1 was indicated as a direct target gene of miR-1271 and knockdown of IRS1 inhibited cell migration, invasion and proliferation in PTC. In addition, miR-1271 inhibited the progression of PTC by targeting IRS1. Besides that, miR-1271 blocked the epithelial-mesenchymal transition (EMT) and protein kinase B (AKT) pathway in PTC. MiR-1271 inhibited the progression of PTC by targeting IRS1 and blocking EMT and AKT pathway.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
MISSION® esiRNA, targeting human IRS1